- Home
- FOLD vs MGEE Comparison
FOLD vs MGEE Comparison
Compare FOLD & MGEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- MGEE
- Stock Information
- Founded
- FOLD 2002
- MGEE 1855
- Country
- FOLD United States
- MGEE United States
- Employees
- FOLD N/A
- MGEE N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- MGEE Electric Utilities: Central
- Sector
- FOLD Health Care
- MGEE Energy
- Exchange
- FOLD Nasdaq
- MGEE Nasdaq
- Market Cap
- FOLD 2.9B
- MGEE 3.3B
- IPO Year
- FOLD 2007
- MGEE N/A
- Fundamental
- Price
- FOLD $6.12
- MGEE $86.25
- Analyst Decision
- FOLD Buy
- MGEE Sell
- Analyst Count
- FOLD 10
- MGEE 1
- Target Price
- FOLD $16.22
- MGEE $74.00
- AVG Volume (30 Days)
- FOLD 5.5M
- MGEE 215.1K
- Earning Date
- FOLD 08-07-2025
- MGEE 08-06-2025
- Dividend Yield
- FOLD N/A
- MGEE 2.04%
- EPS Growth
- FOLD N/A
- MGEE 6.51
- EPS
- FOLD N/A
- MGEE 3.54
- Revenue
- FOLD $543,141,000.00
- MGEE $687,578,000.00
- Revenue This Year
- FOLD $19.87
- MGEE $9.95
- Revenue Next Year
- FOLD $23.15
- MGEE $3.02
- P/E Ratio
- FOLD N/A
- MGEE $24.39
- Revenue Growth
- FOLD 28.25
- MGEE 6.11
- 52 Week Low
- FOLD $5.51
- MGEE $77.16
- 52 Week High
- FOLD $12.65
- MGEE $109.22
- Technical
- Relative Strength Index (RSI)
- FOLD 51.42
- MGEE 38.25
- Support Level
- FOLD $5.66
- MGEE $86.99
- Resistance Level
- FOLD $6.45
- MGEE $89.49
- Average True Range (ATR)
- FOLD 0.21
- MGEE 1.85
- MACD
- FOLD 0.07
- MGEE -0.17
- Stochastic Oscillator
- FOLD 64.89
- MGEE 1.87
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings. MGE's generation mix is 40% coal, 21% renewable energy, 17% natural gas, and third-party purchased power.